University of Perugia

About: University of Perugia is a education organization based out in Perugia, Umbria, Italy. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 13365 authors who have published 39516 publications receiving 1265601 citations. The organization is also known as: Universitá degli Studi di Perugia & Universita degli Studi di Perugia.

Youth unemployment rate and impact of financial crises

Abstract: Purpose – The purpose of this paper is to assess the impact of financial crises on the youth unemployment rate (YUR). The authors consider different types of financial crises (systemic banking crises, non‐systemic banking crises, currency crises and debt crises) and different groups of countries, according to their income level.Design/methodology/approach – After a review of the existing (theoretical and empirical) literature on the determinants of the YUR in general and at the occurrence of economic crises, the authors present empirical estimations on the impact of past financial crises on young workers. The relationship between financial crises and YUR is investigated by employing fixed effects panel estimation on a large panel of countries (about 70) around the world for the period 1980‐2005. The “persistence” over time of the impact is also investigated. Finally the Arellano‐Bond dynamic panel is estimated, confirming the significance of the results.Findings – According to the authors’ empirical estim...

Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease: Data from the PROactive Study (PROactive 08)

Abstract: active) enrolled patients with type 2 diabetes and preexisting cardiovascular disease These patients were at high risk for heart failure, so any therapeutic benefit could potentially be offset by risk of associated heart failure mortality We analyzed the heart failure cases to assess the effects of treatment on morbidity and mortality after reports of serious heart failure RESEARCH DESIGN AND METHODS — PROactive was an outcome study in 5,238 patients randomized to pioglitazone or placebo Patients with New York Heart Association Class II–IV heart failure at screening were excluded A serious adverse event of heart failure was defined as heart failure that required hospitalization or prolonged a hospitalization stay, was fatal or life threatening, or resulted in persistent significant disability or incapacity Heart failure risk was evaluated by multivariate regression RESULTS — More pioglitazone (57%) than placebo patients (41%) had a serious heart failure event during the study (P 0007) However, mortality due to heart failure was similar (25 of 2,605 [096%] for pioglitazone vs 22 of 2,633 [084%] for placebo; P 0639) Among patients with a serious heart failure event, subsequent all-cause mortality was proportionately lower with pioglitazone (40 of 149 [268%] vs 37 of 108 [343%] with placebo; P 01338) Proportionately fewer pioglitazone patients with serious heart failure went on to have an event in the primary (477% with pioglitazone vs 574% with placebo; P 00593) or main secondary end point (349% with pioglitazone vs 472% with placebo; P 0025) CONCLUSIONS — Although the incidence of serious heart failure was increased with pioglitazone versus placebo in the total PROactive population of patients with type 2 diabetes and macrovascular disease, subsequent mortality or morbidity was not increased in patients with serious heart failure Diabetes Care 30:2773–2778, 2007